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SUMMARY – Herpes group viruses (herpes simplex virus, HSV; varicella-zoster virus, VZV; 
cytomegalovirus, CMV; and Epstein-Barr virus, EBV) remain an important cause of morbidity in 
immunocompromised persons. Th e aim of the study was to analyze the prevalence of HSV-1, HSV-2, 
VZV, CMV and EBV in patients undergoing hemodialysis. During a three-year period (2013-2015), 
152 consecutive serum samples from hemodialysis  patients and 150 healthy subjects (control group) 
were tested for the presence of IgM/IgG antibodies to herpes group viruses. Serologic tests were per-
formed using a commercial enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immu-
nofl uorescent assay (ELFA). Hemodialysis patients showed signifi cantly higher CMV IgG seroposi-
tivity compared to controls (88.2% vs. 78.7%, p=0.011). In addition, seroprevalence rates of HSV-1 
and VZV were higher in hemodialysis patients; however, these diff erences did not reach statistical 
signifi cance (85.5% vs. 80.0%, p=0.054 and 99.3% vs. 96.0%, p=0.051, respectively). Th e prevalence of 
HSV-2 and EBV was similar in both groups (12.5% vs. 12.7%, p=0.137 and 98.0% vs. 95.3%, p=0.113, 
respectively). Th ere was no diff erence in IgG seropositivity according to gender and place of residence. 
Logistic regression showed that older age was a signifi cant predictor for CMV and EBV IgG sero-
positivity (increase in age by one year: CMV OR=1.055; 95%CI=1.030-1.080 and EBV OR=1.075, 
95%CI=1.023-1.130).
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Introduction
Members of the herpesvirus family including her-
pes simplex virus (HSV) type 1 and 2, varicella-zoster 
virus (VZV), cytomegalovirus (CMV) and Epstein-
Barr virus (EBV) are distributed worldwide. Preva-
lence rates vary signifi cantly among regions and popu-
lation groups1,2. Herpesviruses are usually spread by 
direct contact with infected saliva (HSV, CMV and 
EBV). VZV is the exception and is spread by airborne 
transmission, while sexual transmission is important 
for HSV type 2 and CMV3. Moreover, herpesviruses 
can be transmitted by blood transfusion and organ 
transplantation4. Th e unique feature of these viruses is 
the ability to establish a latent, nonproductive infec-
tion with the life-long capacity for reactivation to pro-
ductive, lytic infection1.
In immunocompetent persons, primary infections 
are usually asymptomatic or presented as mild, self-
limited disease, i.e. gingivostomatitis or blisters (HSV) 
and infectious mononucleosis syndrome (CMV and 
EBV)3,5,6. Clinical manifestations of VZV infection 
are chickenpox or varicella (primary infection) and 
shingles (reactivation)3. In immunocompromised per-
sons such as transplant recipients, patients with malig-
nant diseases and HIV-infected patients, herpesviruses 
can cause severe, sometimes fatal disease7,8. In this 
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population group, common clinical symptoms include 
retinitis, pneumonitis, hepatitis, esophagitis, meningi-
tis and encephalitis1,9. It has been documented that 
hemodialysis patients have impaired immune response, 
which predisposes them to herpesvirus infections. In-
fections in these patients may be due to a primary in-
fection or, more commonly, by reactivation of latent 
virus or reinfection with exogenous virus (CMV)10,11.
Th ere are many published studies on the prevalence 
of herpes group viruses in the general population; 
however, there are few recent data on hemodialysis pa-
tients.
Th e aim of this study was to analyze the prevalence 
of herpes group viruses in the Croatian patients with 
end-stage renal disease undergoing chronic hemodi-
alysis.
Subjects and Methods
During a three-year period (2013-2015), 152 con-
secutive serum samples from hemodialysis patients 
were tested for the presence of HSV-1/2, VZV, CMV 
and EBV IgM and IgG antibodies at two large Croa-
tian medical institutions (Croatian Institute of Public 
Health and Zagreb University Hospital Center). Con-
trol group included 150 asymptomatic persons pre-
senting for routine testing (antenatal screening, cou-
ples undergoing medically assisted reproduction, or 
elective preoperative check-up) with no symptoms of 
acute febrile disease. Th e mean age of hemodialysis pa-
tients was 53.4±14.5 (range 20-78) years, whereas the 
mean age of control subjects was 46.1±13.2 (range 19-
87) years.
Serologic tests were performed using a commercial 
enzyme-linked immunosorbent assay (ELISA) (Seki-
sui Virotech, Rüsselsheim, Germany) or enzyme-
linked immunofl uorescent assay (ELFA) (Vidas; Bio-
merieux, Marcy l’Etoile, France). VZV, CMV and 
EBV IgM/IgG positive samples were further tested 
for IgG avidity using ELISA (Euroimmun, Lübeck, 
Germany) for confi rmation of recent infection. 
HSV-1/2 IgM/IgG positive samples were confi rmed 
using a western blot test (Euroimmun, Lübeck, Ger-
many).
Statistical analysis
Seroprevalence rates were expressed with 95% con-
fi dence intervals (CI). Diff erences between groups 
were compared using c2 of Fisher exact test. Th e 
strength of association between outcomes (seroposi-
tivity to herpesviruses) and potential risk factors (he-
modialysis, gender, age and setting) was assessed using 
multiple logistic regression: adjusted odds ratios and 
95%CI are presented. Statistical analysis was per-
formed using STATA/IC ver. 14.1 (StataCorp LP, 
USA). Th e level of statistical signifi cance was set at 
p<0.05.
Results
Th e overall prevalence of IgG and IgM antibodies 
to herpes group viruses in hemodialysis patients and 
control subjects is presented in Table 1 a,b. Hemodi-
alysis patients showed signifi cantly higher CMV IgG 
seropositivity compared to controls (88.2% vs. 78.7%, 
p=0.011). Although higher HSV-1 (85.5% vs. 80.0%, 
p=0.054) and VZV (99.3% vs. 96.0%, p=0.051) serop-
revalence rates were also recorded in hemodialysis pa-
tients, these diff erences did not reach statistical sig-
nifi cance. Th e prevalence of HSV-2 and EBV was 
similar in both groups (12.5% vs. 12.7%, p=0.137, and 
98.0% vs. 95.3%, p=0.113, respectively). Acute VZV 
infection (IgM positive) was detected more commonly 
in the control group (4.7% vs. 0.7%, p=0.029). Th ere 
was no diff erence in the prevalence of other herpesvi-
rus infections between patients on hemodialysis and 
control subjects: HSV-1 0% vs. 2.0%, p=0.121; HSV-2 
1.3% vs. 0%, p=0.252; CMV 2.0% vs. 0.7%, p=0.253; 
and EBV 2.6% vs. 2.0%, p=0.278. Using IgG avidity, 
recent primary CMV and EBV infection was detected 
in two control group subjects. In all other IgM/IgG 
positive hemodialysis patients and control subjects, 
IgG antibodies of high avidity were detected indicat-
ing recurrent infection.
Th e IgG seropositivity to herpes group viruses ac-
cording to participant characteristics is presented in 
Tables 2 and 3. Th ere was no diff erence in IgG sero-
positivity between genders. According to age, a sharp 
increase in CMV prevalence was observed in hemodi-
alysis group, from 62.5% in patients aged less than 30 
years to 90.5% in patients aged 31-39 years; thereafter 
the prevalence remained stable (83.9%-92.9%). In the 
control group, seroprevalence was bimodal with an in-
crease in seropositivity from 46.7% in <30 age group to 
71.1% in 31-40 age group and from 72.4% in 41-50 
age group to 95.2% in 51-60 age group. High preva-
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lence rates of VZV and EBV were found in all age 
groups in both hemodialysis patients and control 
group (98.5-100% vs. 96.4-100%, and 87.5-100% vs. 
89.5-100%, respectively). HSV-1 seroprevalence was 
stable in diff erent age groups among hemodialysis pa-
tients (83.9-88.9%), whereas in control subjects it in-
creased progressively by the age of 40 years (53.3-
93.1%) and remained stable thereafter. In hemodialy-
sis patients, HSV-2 seropositivity was highest in the 
youngest age group (25.0%) and varied from 4.8% to 
16.7% in other age groups. In the control group, an 
increase in seropositivity was found starting from 31-
40 group to 51-60 group (7.9%-21.4%) (Fig. 1). Th ere 
was no diff erence in seropositivity between the resi-
dents of urban and rural areas.
Results of logistic regression (Table 4) showed old-
er age to be a signifi cant predictor for CMV and EBV 
IgG seropositivity (increase in age by one year: CMV 
OR=1.055; 95%CI=1.030-1.080; and EBV OR=1.075, 
95%CI=1.023-1.130).
Discussion
Th e results of this study showed a signifi cantly 
higher CMV seropositivity rate in hemodialysis pa-
tients compared to healthy subjects (88.2% vs. 78.7%), 
which is similar to the results of an earlier Croatian 
study (2010-2012; 90.7% vs. 81.9%)12. Similar results 
have been reported from German (83.0% vs. 63.7%-
73.9%) and Turkish (99.6% vs. 82.9%) studies13,14, 
whereas in a Dutch study, the percentage of CMV se-
ropositive hemodialysis patients (68.7%) was in the 
range of the prevalence reported in the general popu-
lation15. A higher prevalence among hemodialysis pa-
tients could be explained by the acquisition of CMV 
through repeated blood transfusions or exposure to 
CMV through contaminated equipment during he-
modialysis procedure.
Although this study found higher seroprevalence 
rates of HSV-1 and VZV in hemodialysis patients, 
these diff erences were not signifi cant (HSV-1 85.5% 
Table 1 a,b. Seroprevalence of herpes group viruses in hemodialysis patients and control subjects
(a)
Group N HSV-1 IgMn/% 95%CI 
HSV-2 IgM
n/% 95%CI
VZV IgM
n/% 95%CI
CMV IgM
n/% 95%CI
EBV IgM
n/% 95%CI
Hemodialysis 152 0/0 0.0-2.4 2/1.3 0.2-4.7 1/0.7 0.1-3.6 3/2.0 0.4-5.7 4/2.6 0.7-6.6
Controls 150 3/2.0 0.4-5.7 0/0 0.0-2.4 7/4.7 1.9-9.4 1/0.7 0.1-3.7 3/2.0 0.4-5.7
p value 0.121 0.252 0.029 0.253 0.278
(b)
Group N HSV-1 IgGn/% 95%CI 
HSV-2 IgG
n/% 95%CI
VZV IgG
n/% 95%CI
CMV IgG
n/% 95%CI
EBV IgG
n/% 95%CI
Hemodialysis 152 130/85.5 78.9-
90.7
19/12.5 7.7-
18.8
151/99.3 96.4-
99.9
134/88.2 81.9-
92.8
149/98.0 93.4-
99.6
Controls 150 120/80.0 72.7-
86.1
19/12.7 7.8-
19.1
144/96.0 91.5-
98.5
118/78.7 71.2-
84.9
143/95.3 90.6-
98.1
p value 0.054 0.137 0.051 0.011 0.113
HSV = herpes simplex virus; VZV = varicella-zoster virus; CMV = cytomegalovirus; EBV = Epstein-Barr virus
Fig. 1. Distribution of study participants 
according to age.
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vs. 80.0%; and VZV 99.3% vs. 96.0%). A study from 
Ahvaz (Iran) showed positive HSV IgG antibodies in 
93.33% of kidney recipients and 77.27% of donors16. 
Seroprevalence rates in Croatian hemodialysis patients 
were high in all age groups (HSV-1 83.9%-88.9% and 
VZV 98.5%-100%). Similar VZV seropositivity was 
noted in some other countries such as Th e Nether-
lands where 97.9% of transplant recipients and 96.8% 
of pre-transplant patients were found to be seroposi-
tive17. In Scotland, hemodialysis patients showed a 
similar seroprevalence of 98.8%18. An Iranian study 
found a very high overall VZV seropositivity (97.9%), 
with a signifi cant diff erence between age groups: 
88.8% in patients aged <40 years, 98.2% in patients 
aged 41-55 and 100% in patients aged >56 years19.
Th e prevalence of HSV-2 was similar in both test-
ed groups in our study (hemodialysis 12.5% and con-
trols 12.7%). Studies from other countries showed a 
wide range of HSV-2 prevalence among hemodialysis 
patients, from 5.4% in Iran20 to 29% in Kosovo21. In 
addition, a Kosovo study found that hemodialysis pa-
tients had about a three-fold greater higher risk of be-
ing HSV-2 seropositive than blood donors21.
Our study showed EBV to be highly prevalent in 
both hemodialysis patients (98.0%) and adult healthy 
population (95.3%). Two Iranian studies addressed the 
prevalence of EBV infection in hemodialysis patients. 
A study conducted from 2005 to 2008 showed 100% 
EBV seropositivity in both potential renal transplant 
donors and transplant recipients22. A more recently 
published study (2011) showed a higher, although not 
statistically signifi cant diff erence in EBV IgG serop-
revalence between re-transplant patients (70%) and 
kidney donors (52%)23.
Th e present study found no signifi cant diff erence 
in herpes group virus seroprevalence between genders, 
which is similar to the results of many other studies 
conducted in hemodialysis patients23-25. However, a 
slightly higher CMV seroprevalence in women was 
noted in some studies26, whereas a Sudanese study has 
reported a slightly higher seroprevalence in men 
(97.9% vs. 93.3%)27.
Our results showed that older age was a signifi cant 
predictor for CMV and EBV seropositivity. Age-relat-
ed increase in the seroprevalence of CMV/EBV anti-
bodies has also been shown in some studies15, whereas 
others found a higher, but not signifi cant diff erence in 
seropositivity in older patients26. In contrast, studies 
from Urmia (Iran) and Gezira (Sudan) showed no re-
lationship of age with CMV seroprevalence27,28.
In conclusion, results of this study indicate that 
herpes group viruses are widely distributed in Croatia. 
Being on hemodialysis is a signifi cant risk factor for 
CMV seropositivity. In addition, older age is a signifi -
cant predictor for both CMV and EBV seropositivity.
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Sažetak
SEROPREVALENCIJA NA VIRUSE IZ HERPES GRUPE U BOLESNIKA NA HEMODIJALIZI
T. Vilibić-Čavlek, B. Kolarić, M. Bogdanić, I. Tabain i N. Beader
Virusi iz herpes grupe (herpes simpleks virus, HSV; varičela-zoster virus, VZV; citomegalovirus, CMV; Epstein-Barrov 
virus, EBV) su značajan uzrok smrtnosti u imunokompromitiranih osoba. Cilj rada bio je analizirati učestalost HSV-1, 
HSV-2, VZV, CMV i EBV u bolesnika koji se liječe hemodijalizom. Tijekom trogodišnjeg razdoblja (2013.-2015.) ispitano 
je ukupno 152 uzastopno pristiglih uzoraka seruma bolesnika na hemodijalizi te 150 uzoraka seruma zdravih osoba (kon-
trolna skupina) na prisutnost herpes virusnih IgM/IgG protutijela. Serološko testiranje učinjeno je pomoću komercijalnog 
dijagnostičkog imunoenzimnog testa (ELISA) ili imunoenzimnog testa s fl uorescentnom detekcijom (ELFA). Bolesnici na 
hemodijalizi bili su značajno češće CMV IgG seropozitivni u odnosu na kontrolnu skupinu (88,2% prema 78,7%, p=0,011). 
Nadalje, seroprevalencija HSV-1 i VZV također je bila viša u bolesnika na hemodijalizi, no statistička značajnost nije do-
stignuta (85,5% prema 80,0%, p=0,054; 99,3% prema 96,0%, p=0,051). Učestalost HSV-2 i EBV protutijela nije se razliko-
vala između skupina (12,5% prema 12,7%, p=0,137, odnosno 98,0% prema 95,3%, p=0,113). IgG seroprevalencija nije se 
razlikovala u odnosu na spol i mjesto prebivališta. Rezultati logističke regresije pokazali su da je starija životna dob značajan 
čimbenik rizika za CMV i EBV seropozitivnost (porastom dobi za jednu godinu CMV OR=1,055; 95%CI=1,030-1,080; 
EBV OR=1,075, 95%CI=1,023-1,130).
Ključne riječi: Herpesvirus 1, humani; Herpesvirus 3, humani; Citomegalovirus, herpesvirus 4, humani; Hemodijaliza; Hrvatska
